{"id":980479,"date":"2026-07-09T16:33:47","date_gmt":"2026-07-09T20:33:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/"},"modified":"2026-07-09T16:33:47","modified_gmt":"2026-07-09T20:33:47","slug":"bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/","title":{"rendered":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPhase 2 study did not meet its primary endpoint.<\/p>\n<\/li>\n<li>\nCompany will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy.<\/p>\n<\/li>\n<li>\nPortfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months.<\/p>\n<\/li>\n<\/ul>\n<p>VAUGHAN, Ontario&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1\/2a study following 28 days of topical administration. Based on the totality of the data, the company has decided not to advance the program in this indication as a topical eye drop.<\/p>\n<p>\n\u201cSuccess in drug development is based on a portfolio, not a single program,\u201d said Yehia Hashad, MD, executive vice president, R&amp;D and chief medical officer, Bausch + Lomb. \u201cWe\u2019ve intentionally built a diversified pipeline because we know innovation requires pursuing multiple scientific hypotheses simultaneously. Not every program will succeed, but every study helps us make smarter decisions about where to invest.\u201d<\/p>\n<p>\nBausch + Lomb <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.bausch.com%2Fpress-releases%2Fbausch-lomb-bolsters-pipeline-acquisition-whitecap-biosciences&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=acquired&amp;index=1&amp;md5=bbac302b8e51ec0583539df8f5c11b46\">acquired<\/a> Whitecap Biosciences in 2025 primarily for the promise of developing a sustained-release implant for the treatment of geographic atrophy (GA). BL1107 (originally referred to as WB007) also showed intriguing clinical results \u2013 with a small sample size \u2013 for improving visual acuity in glaucoma patients. The company made a strategic decision to pursue both indications and will now focus solely on developing the first small-molecule sustained-release implant for GA. Bausch + Lomb expects clinical trials to begin in 2028 and will continue to collaborate on the candidate with Ripple Therapeutics, whose patented technology platform is based on a discovery that drugs can be chemically engineered into controlled-release pharmaceuticals without the use of polymers.<\/p>\n<p><b>Pipeline momentum continues<\/b><\/p>\n<p>\nBausch + Lomb\u2019s portfolio reflects a deliberate strategy to diversify innovation across Consumer, Pharmaceuticals, Surgical and Vision Care segments rather than relying on any single asset or therapeutic area. This approach positions the company to generate multiple clinical, regulatory and commercial milestones over the coming years while supporting sustainable growth well into the next decade.<\/p>\n<p><b>Study results<\/b><\/p>\n<p>\nThe randomized, double-masked, three-arm, parallel-group study enrolled 159 adults aged 18 and older with primary open-angle glaucoma or ocular hypertension. The study did not meet its primary endpoint, defined as change from baseline in visual field mean deviation at Day 28 (Exit, Hour 2).<\/p>\n<p>\nKey secondary endpoints assessing visual function, including low-luminance best-corrected visual acuity responder rates, were also not achieved. Evidence of ocular target engagement was observed, as demonstrated by meeting a secondary endpoint of a reduction in intraocular pressure at Day 28 (Exit, Hour 2).<\/p>\n<p>\nThe safety profile was consistent with prior clinical experience with BL1107, with no new safety signals identified.<\/p>\n<p><b>About Bausch + Lomb<\/b><\/p>\n<p>\nOur mission is simple \u2013 we help people see better to live better, all over the world. For nearly two centuries we\u2019ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we\u2019re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bausch.com%2F&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=www.bausch.com&amp;index=2&amp;md5=89fb4e8230c0b6fed50a2b840d87b05c\">www.bausch.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FBauschandLomb&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=3af669e68a9adc92511f9fa078e8f391\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fbauschlomb%2F%3Fhl%3Den&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=fa13273bdc1233f14b57393bb32a5afb\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F5185%2Fadmin%2F&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=5b88811e445d41c8cb66b6289407ef76\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FBauschLomb&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=X&amp;index=6&amp;md5=8dd527db7f734692bd5c25720d54b01d\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fbauschlomb1&amp;esheet=54568159&amp;newsitemid=20260709686233&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=a39c18166d79851c7e16a407adcd48d0\">YouTube<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d). Forward-looking statements may generally be identified by the use of the words \u201canticipates,\u201d \u201cseeks,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cpending\u201d or \u201cproposed\u201d and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb\u2019s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260709686233\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260709686233\/en\/<\/a><\/span><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Caryn Marshall<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:caryn.marshall@bausch.com\">caryn.marshall@bausch.com<br \/>\n<\/a><br \/>(908) 493-1381<\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>George Gadkowski<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:george.gadkowski@bausch.com\">george.gadkowski@bausch.com<br \/>\n<\/a><br \/>(877) 354-3705 (toll-free)<\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Optical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260709686233\/en\/1668940\/3\/Bausch_Lomb_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. VAUGHAN, Ontario&#8211;(BUSINESS WIRE)&#8211; Bausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-980479","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. VAUGHAN, Ontario&#8211;(BUSINESS WIRE)&#8211; Bausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function &hellip; Continue reading &quot;Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-09T20:33:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate\",\"datePublished\":\"2026-07-09T20:33:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/\"},\"wordCount\":819,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/\",\"name\":\"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-09T20:33:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/","og_locale":"en_US","og_type":"article","og_title":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk","og_description":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. VAUGHAN, Ontario&#8211;(BUSINESS WIRE)&#8211; Bausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function &hellip; Continue reading \"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-09T20:33:47+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate","datePublished":"2026-07-09T20:33:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/"},"wordCount":819,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/","name":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-09T20:33:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260709686233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-announces-phase-2-results-for-glaucoma-neuroprotective-candidate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=980479"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980479\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=980479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=980479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=980479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}